Andere talen Abbisko Cayman Limited

Aandelen

2256

KYG0028A1085

Vertraagde tijd Hong Kong S.E. Andere beurzen 08:48:01 19-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
2,91 ^HKD	+1,75%		-0,68%	-20,27%

10/04	Abbisko Cayman's afdeling presenteert preklinische studie van medicijn tegen leverkanker op jaarlijkse bijeenkomst van AACR	MT
09/04	Abbisko Cayman voltooit de patiëntenregistratie voor fase 3-studie van de behandeling van gewrichtstumoren	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Abbisko Cayman's Unit Presents Pre-Clinical Study of Liver Cancer Drug at AACR Annual Meeting	10/04
Abbisko Cayman Completes Patient Enrollment for Phase 3 Trial of Joint Tumor Treatment	09/04
Abbisko Therapeutics Co., Ltd. Completes All Patient Enrollment for the Global Phase III TGCT Trial of Its CSF-1R Inhibitor - Pimicotinib	09/04
Abbisko Cayman's Attributable Loss Narrows as Revenue, Other Gains Rise	14/03
Abbisko Cayman to Buy Back, Cancel Up to HK$100 Million Shares	13/03
Abbisko Cayman Limited commences an Equity Buyback for 70,219,935 shares, representing 10% of its issued share capital, under the authorization approved on June 14, 2023.	13/03
Abbisko Cayman Limited Reports Earnings Results for the Full Year Ended December 31, 2023	12/03
Abbisko Cayman Completes Dosing for Phase 1 Trials for Lung Cancer Treatment	23/02
Abbisko Cayman Receives $70 Million Upfront Payment for Licensing of Tumor Treatment	06/02
Abbisko Cayman Trustee Buys 6.1 Million Shares Under Restricted Share Scheme	02/02
European Medicines Agency Grants Orphan Drug Designation to Abbisko's Tumor Drug	09/01
Abbisko Therapeutic announces that EMA has granted orphan drug designation for its CSF-1R inhibitor Pimicotinib （ABSK021）	09/01
Abbisko Cayman Doses First Participant in Phase 1 Trial for Anti-Tumor Treatment; Shares Fall 3%	03/01
Abbisko Therapeutics Co., Ltd. Completes the First Patient Dose in the Clinical Trial for Its Next-Generation CD73 Inhibitor ABSK051	03/01
Abbisko Cayman Unit Gets US FDA Fast-Track Status for Tenosynovial Giant Cell Tumor Treatment	14/12
Abbisko Therapeutics Announces U.S. FDA Grants Fast Track Designation for CSF-1R Inhibitor Pimicotinib	14/12
Abbisko Therapeutics Announced the Entry into a Licensing Agreement for Pimicotinib (ABSK021) with Merck	04/12
Abbisko Cayman Doses First Patient in Phase 2 Trial for Pancreatic Cancer Treatment	28/11
Abbisko Therapeutics Completed the First Patient Dose in the Phase II Advanced Pancreatic Cancer Trial of CSF-1R Inhibitor Pimicotinib in China	27/11
China Approves Abbisko Cayman Subsidiary's Clinical Trial for Tumor Drug	09/11

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Abbisko Cayman Limited

Aandelen

2256

KYG0028A1085

Andere talen

Filters